Mylan to buy Agila Specialties from India's Strides for $1.6 bln

Wed Feb 27, 2013 5:11pm EST

Feb 27 (Reuters) - Generic drugmaker Mylan Inc said it would buy Agila Specialties from India's Strides Arcolab Ltd for $1.6 billion to expand its injectable drugs business.

Mylan, one of the world's largest generic drugmakers with more than 1,100 products, said the acquisition is expected to immediately add to Mylan's adjusted diluted earnings per share following closing.

Mylan said the deal was unanimously approved by its board.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.